Concerns about the potential side effects of Biogen Idec Inc. (NASDAQ:BIIB)’s key multiple-sclerosis pill Tecfidera overshadowed the strong third-quarter results the biotech company Tecfidera is an essential part of Biogen’s goal to become the dominant maker of multiple-sclerosis treatments, a group of drugs that command high prices and that patients typically take for years. Tecfidera’s sales in the third quarter more than doubled to $787.1 million, up from $286.4 million a year earlier. Tysabri, meanwhile, posted a 25% increase in sales. . Biogen Idec Inc. (NASDAQ:BIIB) belongs to Healthcare sector. Its net profit margin is 25.60% and weekly performance is 1.11%. On last trading day company shares ended up $309.07. Biogen Idec Inc. (NASDAQ:BIIB) distance from 50-day simple moving average (SMA50) is -6.08%.

On Oct 20, Texas Instruments Inc. (NASDAQ:TXN) posted third-quarter results above expectations and its CFO said business was healthy, in contrast to recent concerns on Wall Street about a possible slowdown in chip demand. The company reported quarterly revenue of $3.50 billion, up 8 percent from the year-ago period. It forecast fourth-quarter revenue of $3.13 billion to $3.39 billion. The mid-point of TI’s revenue guidance is about $26 billion. Texas Instruments Inc. (NASDAQ:TXN) shares moved down -0.32% in last trading session and ended the day at $46.62. TXN Gross Margin is 55.00% and its return on assets is 12.10%. Texas Instruments Inc. (NASDAQ:TXN) quarterly performance is -2.59%.

Brookfield Property Partners L.P. (NYSE:BPY), said it plans to reopen the property as it expands its investments in gambling venues. Brookfield Wednesday said it won the bankrupt casino property with a $110 million bid in an auction that ended at 5:30 a.m. New York time. On 22 October, Brookfield Property Partners L.P. (NYSE:BPY) shares moved down -0.46% and was closed at $21.70. BPY EPS growth in last 5 year was 0.00%. Brookfield Property Partners L.P. (NYSE:BPY) year to date (YTD) performance is 12.90%.

Zacks lowered shares of Virtus Investment Partners (NASDAQ:VRTS) from a neutral rating to an underperform rating in a report released on Thursday. Zacks currently has $165.60 price objective on the stock. Virtus Investment Partners, Inc. (NASDAQ:VRTS) ended the last trading day at $168.86. Company weekly volatility is calculated as 5.39% and price to cash ratio as 8.43. Virtus Investment Partners, Inc. (NASDAQ:VRTS) showed a weekly performance of 0.78%.

On OCT. 20, Constellation Brands Inc. (NYSE:STZ), announced that it priced the public offering of $800 million aggregate principal amount of Senior Notes, consisting of $400 million of 3.875% Senior Notes due 2019 and $400 million of 4.750% Senior Notes due 2024 (collectively, the “notes”). Constellation Brands Inc. (NYSE:STZ) shares advanced 0.29% in last trading session and ended the day at $86.91. STZ Gross Margin is 43.20% and its return on assets is 5.30%. Constellation Brands Inc. (NYSE:STZ) quarterly performance is -0.39%.